Navigation Links
Largest Multi-Centre Evaluation of Radioembolization Using Sir-Spheres for Patients With Inoperable Primary Liver Cancer Published in Hepatology
Date:7/7/2011

PAMPLONA, Spain, July 7, 2011 /PRNewswire/ --


 

Results of the multi-centre European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY) analysis of the long-term outcomes related to survival and safety of radioembolization using SIR-Spheres in patients with inoperable primary liver tumours were published on-line today in Hepatology, the peer-reviewed journal of the American Association of the Study of Liver Diseases.[1]

Evaluation of 325 patients with inoperable primary liver cancer (unresectable hepatocellular carcinoma), who were treated by teams of liver specialists, oncologists, interventional radiologists and nuclear medicine physicians at eight centres in Germany, Italy and Spain, provided "robust evidence of the survival outcomes achieved with radioembolization, including patients with advanced disease and few treatment options," said Bruno Sangro, MD, PhD, Professor of Hepatology in the Liver Unit of the Clinical University of Navarra, Pamplona, Spain, and chair of the ENRY group.

About Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) occurs in people whose livers have become severely damaged or cirrhotic, due to conditions such as hepatitis and alcoholism.  It is one of the ten most-common cancers in the world, with nearly 750,000 cases diagnosed annually, and the third-leading cause of cancer deaths.[2]  It occurs with greatest frequency in regions where hepatitis is most often diagnosed, such as in Asia Pacific and Southern Europe.  

Hepatocellular cancer can be cured only by surgery, either by resecting the diseased parts of the liver, or by transplantation with a liver from a healthy donor.  These interventions, however, are inappropriate for the great majority of patients, whose survival may range from a few months to two or more years depending largely on the state of their liver at the time of their diagnosis and the extent of tumour invasion.

Findings of the ENRY Evaluation

The majority of the patients (82.5%) evaluated by the ENRY group had liver disease that was reasonably-well compensated (Child-Pugh class A), with underlying cirrhosis (78.5%) and good ECOG Performance status (ECOG 0-1: 87.7%).  However, many of them had multiple tumour nodes (75.9%), with disease present in both lobes of the liver (53.1%) and/or occlusion of the portal vein (the vessel that transports blood from the gastrointestinal tract to the liver) in either a branch of the vein (13.5%) or the main vessel (9.8%).

Over 40 per cent of the patients (41.5%) had progressed following one or more other treatments prior to receiving radioembolization with SIR-Spheres (yttrium-90 resin microspheres; Sirtex Medical Limited, Sydney, Australia), including surgery or liver transplantation, percutaneous procedures such as ethanol injection or radiofrequency ablation of individual liver tumours, or vascular procedures such as transarterial embolisation (TAE) or chemoembolisation (TACE) that block the liver arteries that feed tumours.

Using Barcelona Clinic Liver Cancer (BCLC) staging criteria, the vast majority of patients evaluated by the ENRY group had either advanced (BCLC C: 56.3%) or intermediate (BCLC B: 26.8%) disease.

The patients who received radioembolization (also called selective internal radiation therapy or SIRT) were administered a median dose of 1.6 GBq of beta-radiating yttrium-90 resin microspheres, predominately as a single procedure delivered transarterially to the liver via a catheter through the femoral and hepatic arteries.  The median overall survival of the SIRT-treated patients evaluated by the ENRY group was 12.8 months.  Survival varied significantly by disease stage: 24.4 months for patients in BCLC A; 16.9 months in BCLC B; and 10.0 months in BCLC C.  

"As ENRY was not a prospective study, our findings must be interpreted conservatively," Professor Sangro explained.  "What we can say, based on our evaluation of a broad range of patients with HCC treated in routine clinical practice, is that radioembolization using SIR-Spheres directly targets tumours and spares viable liver tissue, which enables us to reduce the burden of disease and potentially increase both the patient's survival and quality of life.  The greatest survival benefit can be expected in those patients with better performance status, fewer tumour nodules and no occlusion of the portal vein.  

"It is also clear from our analysis," he added, "that radioembolization may be particularly helpful in four specific patient populations.  These include, firstly, patients who might otherwise be considered for TACE but may benefit more from SIR-Spheres; patients who are poor candidates for TACE due to the high number of tumour nodules (>5) or spread to both lobes of the liver; patients who have previously failed TACE; and, finally, patients who are ineligible for TACE because of portal vein occlusion.  These patients have few other treatment options."

Other treatment options that have been demonstrated to extend survival for patients with inoperable HCC include TACE, which requires repeated interventional procedures and hospitalisation due to the resulting post-embolisation syndrome; and sorafenib, an oral medication taken twice daily which can give side effects leading to discontinuation of the drug in more than a third of patients (38%).[3]

The ENRY collaboration found that radioembolization was very well-tolerated by these otherwise ill patients.  More than half (54.5%) experienced fatigue; around one third (32.0%) reported nausea or vomiting; while slightly more than a quarter (27.1%) reported abdominal pain and one in ten reported a mild fever.  These symptoms were transient in all cases.

A very small number of patients (3.7%) suffered from gastrointestinal ulceration, which can occur when some microspheres inadvertently pass into a gastric artery.  

"Based on the ENRY evaluation," Prof Sangro concluded, "we believe that radioembolization merits routine use in a number of patients with primary liver cancer.  Radioembolization may also be a synergistic option when combined with newer pharmaceutical treatments, such as the tyrosine kinase inhibitor, sorafenib."    

Physicians and patients interested in participating in either of two recently-initiated randomised controlled trials of radioembolization using SIR-Spheres may learn more at:


For Further Information:

SIR-Spheres are fully FDA-approved and are indicated in the U.S. for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine.

SIR-Spheres are also approved for use in Australia, the European Union (CE Mark), New Zealand, Switzerland, Turkey and several other countries for the treatment of unresectable liver tumours.

Downloadable images, media background information, a mode of action video and further supporting materials are available online at http://www.SIRTnewsroom.com.

References:

  1. Sangro B, Carpanese L, Cianni R et al on behalf of European Network on Radioembolization with Yttrium-90 resin microspheres (ENRY). Survival after [90]Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation.  Hepatology 2011; ePub doi: 10.1002/hep.24451.
  2. GLOBOCAN.  Liver Cancer Incidence and Mortality Worldwide in 2008.  http://globocan.iarc.fr/factsheets/cancers/liver.asp accessed 28 June 2011.
  3. Llovet J, Ricci S, Mazzaferro V et al for the SHARP Investigators Study Group.  Sorafenib in advanced hepatocellular carcinoma.  New England Journal of Medicine 2008; 359: 378-390.

For further information:
Kassidie Blackstock
Fleishman Hillard
+1-919-457-0749 / +1-865-776-6827
Kassidie.Blackstock@fleishman.com

Sarah Hoffman
Aurora Healthcare Communications
+44(0)207-148-4176 / +44(0)7809-127-499
sarah@auroracomms.com



'/>"/>
SOURCE ENRY Trialists
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
5. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
10. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
11. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Give To ... users to search for and donate to Give To Cure’s campaign that is crowdfunding ... that lets users make and share payments through a smart device. In 2015 alone, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
(Date:2/5/2016)... ... 05, 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of ... Day to individuals in need. The event is scheduled to take place on February ... is to provide dental care to community members in need. Each patient will be ...
Breaking Medicine News(10 mins):